Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Durata Therapeutics Company Profile (NASDAQ:DRTX)

Consensus Ratings for Durata Therapeutics (NASDAQ:DRTX) (?)
Ratings Breakdown: 6 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $20.51 (14.46% downside)

Current Analysts' Coverage Summary for Durata Therapeutics (NASDAQ:DRTX)
Show:
DateFirmActionRatingPrice TargetDetailsShare
10/15/2014Roth CapitalDowngradeBuy -> Neutral$23.00ViewTweet This Rating  Share This Rating on StockTwits
10/14/2014Credit SuisseDowngradeOutperform -> Neutral$25.00ViewTweet This Rating  Share This Rating on StockTwits
10/7/2014ZacksUpgradeNeutral -> Outperform$29.10ViewTweet This Rating  Share This Rating on StockTwits
10/7/2014RBC CapitalDowngradeOutperform -> Sector PerformViewTweet This Rating  Share This Rating on StockTwits
10/6/2014JMP SecuritiesDowngradeOutperform -> Market PerformViewTweet This Rating  Share This Rating on StockTwits
8/8/2014Jefferies GroupLower Price Target$15.00 -> $12.00ViewTweet This Rating  Share This Rating on StockTwits
6/20/2014GabelliInitiated CoverageHoldViewTweet This Rating  Share This Rating on StockTwits
5/23/2014MLV & Co Initiated CoverageBuy$21.00ViewTweet This Rating  Share This Rating on StockTwits
4/9/2014Summer StreetInitiated CoverageBuy$22.00ViewTweet This Rating  Share This Rating on StockTwits
3/6/2014Craig HallumInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
12/2/2013WedbushDowngradeOutperform -> Neutral$13.00ViewTweet This Rating  Share This Rating on StockTwits
11/13/2013Janney Montgomery ScottInitiated CoverageBuy$19.00ViewTweet This Rating  Share This Rating on StockTwits
5/4/2013Ativo ResearchInitiated CoverageMost UnfavorableViewTweet This Rating  Share This Rating on StockTwits
2/25/2013Bank of AmericaReiterated RatingBuy$12.00 -> $14.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/25/2012 forward)
Discuss Durata Therapeutics